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Background: Some trial have demonstrated a beneﬁt of adjuvant ﬂuoropirimidine with or without platinum compounds
compared with surgery alone. ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI [irino-
tecan plus 5-ﬂuorouracil/folinic acid (5-FU/LV)] followed by docetaxel plus cisplatin improves disease-free survival in com-
parison with 5-FU/LV in patients with radically resected gastric cancer.
Patients and methods: Patients with resectable adenocarcinoma of the stomach or gastroesophageal junction
were randomly assigned to either FOLFIRI (irinotecan 180 mg/m2 day 1, LV 100 mg/m2 as 2 h infusion and 5-FU 400 mg/m2
as bolus, days 1 and 2 followed by 600 mg/m2/day as 22 h continuous infusion, q14 for four cycles) followed by docetaxel
75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, q21 for three cycles (sequential arm) or De Gramont regimen (5-FU/LV arm).
Results: From February 2005 to August 2009, 1106 patients were enrolled, and 1100 included in the analysis: 562 in
the sequential arm and 538 in the 5-FU/LV arm. With a median follow-up of 57.4 months, 581 patients recurred or died
(297 sequential arm and 284 5-FU/LV arm), and 483 died (243 and 240, respectively). No statistically signiﬁcant difference
was detected for both disease-free [hazard ratio (HR) 1.00; 95% conﬁdence interval (CI): 0.85–1.17; P = 0.974] and
overall survival (OS) (HR 0.98; 95% CI: 0.82–1.18; P = 0.865). Five-year disease-free and OS rates were 44.6% and
44.6%, 51.0% and 50.6% in the sequential and 5-FU/LV arm, respectively.
Conclusions: A more intensive regimen failed to show any beneﬁt in disease-free and OS versus monotherapy.
Clinical trial registration: ClinicalTrials.gov Identiﬁer: NCT01640782.
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introduction
Gastric cancer (GC) is the second leading cause of cancer mortality
in the world. Surgical resection remains the only potentially cura-
tive treatment, but recurrence rate of 40%–80% is still high [1].
An individual patient meta-analysis showed that in patients
with resected GC, an adjuvant ﬂuorouracil (5-FU)-based che-
motherapy provides a statistically signiﬁcant beneﬁt in terms of
overall survival (OS) and disease-free survival (DFS) [2].
During the past decade, different studies have clariﬁed the
beneﬁt of a D2 gastrectomy [i.e. systematic removal of the ﬁrst
(perigastric) and second (celiac artery and its branches) level
lymph nodes] and that surgical under-treatment can negatively
affect survival cancer related [3, 4]. Thus, D2 gastrectomy is now
worldwide accepted as standard surgery, while the optimal adju-
vant therapy after surgery has not yet been established.
The efﬁcacy of 1-year adjuvant treatment with S-1 compared
with surgery alone in stage II–III patients who underwent a D2
gastrectomy was reported by the AGTS-GC Investigators in 2007
[5] and recently conﬁrmed on the basis of 5-year follow-up [6].
Fluoropyrimidine, platinum-based compounds, taxanes, and
irinotecan (CPT-11) represent the backbone for most GC treat-
ments. Two-drug platinum or ﬂuoropirimidine schemes have
shown similar efﬁcacy and different toxicity proﬁle. Since three-
drug combinations—although feasible—are characterized by
signiﬁcant toxicity, an alternative strategy could be the use of se-
quential chemotherapy in which active and non-cross-resistant
drugs are administered at their maximum doses.
Actually, the feasibility of a sequential treatment of CPT-11
plus 5-FU/LV (FOLFIRI) followed by docetaxel plus cisplatin
(TXT/CDDP) has been previously demonstrated in the adjuvant
setting [7].
Therefore, ITACA-S (Intergroup Trial of Adjuvant Chemo-
therapy in Adenocarcinoma of the Stomach Trial) study
(ClinicalTrials.gov Identiﬁer: NCT01640782) was designed to
evaluate whether an adjuvant polychemotherapy with FOLFIRI
and TXT/CDDP improves the outcome of patients who under-
went radical resection with extended lymph nodes dissection in
comparison with a monotherapy with 5-FU/LV.
methods
study design
This was a multicenter, randomized, open-label, active-controlled, of super-
iority, phase III trial. Patients were randomly assigned to one of the two ad-
juvant chemotherapy regimens, using a centrally managed, computer-
generated, permuted-block randomization scheme, with a 1:1 ratio, stratiﬁed
by center and nodal involvement [no positive nodes (pN−) versus ≥1 posi-
tive node (pN+)].
An independent data monitoring committee, which annually met to
review accrual, safety, and efﬁcacy, monitored the study. No formal stopping
rules were adopted.
The Istituto di Ricerche Farmacologiche ‘Mario Negri’ played the role of
not-for-proﬁt sponsor. Eleven oncological groups collaborated with the
sponsor in the planning and management of the study.
eligibility criteria
The inclusion criteria were: a histologically proven diagnosis of adenocarcin-
oma of the stomach or gastroesophageal junction; radical resection of tumor
no more than 8 weeks before the randomization without gross or microsco-
scopic evidence of residual disease; pN+ or pN− patients with pT2b-3–4
according to the International Union Against Cancer (UICC) [8]; Eastern
Cooperative Oncology Group performance status (ECOG-PS) < 2; age≤ 75
years; no previous malignancies other than superﬁcial skin cancer or in situ
cervical carcinoma; no previous chemotherapy or radiotherapy; and no evi-
dence of abnormal hepatic, renal, or cardiac function.
In each centre, study protocol had to be approved by institutional review
board and a written informed consent of subjects had to be given before any
study-related activities were carried out.
surgery
Surgical procedures were not standardized among participating centers. The
minimum surgical recommendations included total or subtotal gastrectomy
with negative resection margins with at least a D1 (i.e. lymphadenectomy of
the perigastric lymph nodes) dissection.
treatment plan
In the experimental sequential arm, treatment consisted in CPT-11 180 mg/m2
1 h infusion day 1, LV 100 mg/m2 2 h infusion days 1–2 and 5-FU 400 mg/m2
as bolus followed by daily 22 h infusion of 600 mg/m2, q14 for four cycles
and after 3 weeks docetaxel 75 mg/m2 1 h infusion day 1, followed by cisplatin
75 mg/m2 day 1, q 21; for three cycles. Dexamethasone was recommended
before, 12 and 24 h after docetaxel.
In the control 5-FU/LV group, according to De Gramont regimen, patients
were given LV 100 mg/m2 2 h infusion days 1–2 and 5-FU 400 mg/m2 as bolus
followed by daily 22 h infusion of 600 mg/m2 every 14 days for nine cycles.
Pre-speciﬁed dose modiﬁcations were done for patients who experienced
hematologic and non-hematologic toxicities. Growth factors were permitted
for prolonged or complicated severe neutropenia.
assessments
Adjuvant baseline assessment included a history taking: physical examin-
ation, routine hematologic/biochemical tests, electrocardiogram, pregnancy
test, CEA and CA-19.9, abdominal ultrasonography and/or computed tom-
ography (CT), chest X-ray, and bone scan.
Before each chemotherapy cycle, physical examination and laboratory
tests had to be repeated. At the end of chemotherapy treatment, physical
examination, vital signs, laboratory tests, CT scan, and tumor markers were
required. Follow-up visits were done every 4 months for the ﬁrst 3 years;
then at 8-month intervals up to the ﬁfth year, and thereafter at investigator’s
discretion. Follow-up consisted of a physical examination, routine laboratory
tests, abdominal CT scan, gastroscopy, and chest X-ray. Site and date of the
ﬁrst recurrence and, if patient died, the date of death were recorded. Disease
recurrence (loco-regional and/or metastatic disease) was determined by clin-
ical, radiologic, and, whenever possible, histological examination.
All adverse events were graded according the National Cancer Institute-
Common Toxicity Criteria (NCI-CTC), version 2.0.
statistical methods
The primary end point was DFS; secondary outcomes were OS, treatment
compliance, and tolerability. We deﬁned DFS as the time from randomiza-
tion to ﬁrst appearance of recurrence/death from any cause; patients known
to be alive and without disease at the time of analysis were censored at their
last follow-up. OS was deﬁned as the time from randomization to death from
any cause; patients known to be alive at the time of analysis were censored at
their last follow-up.
Expecting a 3-year DFS around 50% in the5-FU/LV group, we set an
accrual target of ∼1100 patients to observe 636 recurrences/deaths. This
number of events was required to detect an absolute DFS difference of 7%,
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corresponding to a hazard ratio (HR) of 0.80 with 80% power at 5% signiﬁ-
cance level. Both accrual and follow-up lengths were 3 years.
We compared the Kaplan–Meier curves for survival with the Mantel–Cox
version of log-rank test. ACox proportional hazards model was used to estimate
treatment effect adjusted for prognostic factors, such as stage, number of positive
nodes, and tumor site. The differences in relative effect size in selected subgroups
were described by forest plots of HR and relative conﬁdence interval (CI) in
each level of factors considered, and tested with the χ2 test for interaction.
To test for differences in tolerability, we used a χ2 test for trend.
Analyses were done by intention to treat, except for those of compliance
and tolerability carried out considering patients in the arm of the treatment
they actually received. All reported P-values are two-sided, and CIs are at
95% level (95% CIs).
Analyses were carried out using SAS statistical software, version 9.1.3
(SAS Institute Inc., Cary, NC).
results
From February 2005 to August 2009, 1106 patients were en-
rolled by 104 centers. Six patients, ﬁve with metastatic disease
and one randomized by mistake, were excluded. Therefore, the
analysis was carried out on 1100 patients, 562 in the sequential
arm and 538 in the 5-FU/LV arm (supplementary Figure S1,
available at Annals of Oncology online).
As shown in supplementary Table S2, available at Annals of
Oncology online, patient and tumor characteristics were well
balanced between the two treatment groups.
surgery
A D1 lymphadenectomy was carried out in 25% of patients, while
most patients undergone a D2 lymphadenectomy (72%). The
median number of lymph nodes removed per patient was 27 in
both arms. Fifty-ﬁve percent of the patients underwent a total
gastrectomy.
compliance
Twenty-eight patients, 12 in the sequential and 16 in the 5-FU/
LV arm, did not start chemotherapy, mainly due to treatment
refusal. Further two and four patients, respectively, crossed
treatment and for the analysis of compliance and toxicity were
analyzed in the arm of treatment they actually received.
Of the 520 patients who started 5-FU/LV, 450 (86.5%) com-
pleted the treatment, 70 (13.5%) stopped it because of toxicity (n
= 30), relapse/death (n = 20), or other reasons (n = 20). Among
patients who completed treatment, a dose reduction and/or a
time modiﬁcation was required in 265 patients (58.9%).
Out of 552 who started the sequential treatment, 421 (76.3%)
completed it, 131 (23.7%) stopped chemotherapy because of
toxicity (n = 83), relapse/death (n = 11), refusal (n = 29), or
other reasons (n = 8). Only 92 patients (16.7%) completed treat-
ment without time and dose changes.
The median number of cycles administered was nine, ranging
from one to nine, and seven, ranging from one to seven, in 5-
FU/LV and sequential treatment, respectively.
toxicity
The observed toxic effects are summarized in supplementary
Table S3, available at Annals of Oncology online. As expected,
the polychemotherapy was less tolerated, with a more frequent
grade 3–4 episodes for almost all toxicities. Overall, a grade 3–4
toxic episode (also grade 2 for neurotoxicity) was reported at
least once in 361 (65.4%) and 99 (19.0%) patients in the sequen-
tial and 5-FU/LV arm, respectively. Hematological and gastro-
intestinal (i.e. nausea, vomiting and diarrhea) toxicities
predominated. The most common hematological toxicity was
neutropenia. Three toxic deaths occurred: one in the 5-FU/LV
arm for mucositis and two in the sequential arm due to stupor
condition and diarrhea/vomiting.
disease-free and overall survival
On 21 January 2013, the median follow-up was 57.4 months in
the 5-FU/LV and 56.0 months in the sequential arm. Since we
observed 91% of the target events for DFS and 96% of the
patients recurred/died or were followed for more than 3 years,
we decided to perform the ﬁnal analysis. Given the data
observed, both under original hypothesis and current trend, the
probability to reach a statistically signiﬁcant result at the target
number of events was <0.0001.
Recurrence was observed in 518 patients: 262 (46.6%) in the
sequential arm and 256 (47.6%) in the 5-FU/LV arm, without
difference in the pattern of ﬁrst sign of recurrence. In both
arms, most patients had a metastatic disease (79.8% in the se-
quential and 83.6% in the 5-FU/LV arm), while loco-regional
recurrence occurred in 10.4% and 9.4% patients, respectively.
Twenty-three (8.8%) patients in the sequential and 18 (7.0%)
in the 5-FU/LV arm had both loco-regional recurrence and
metastatic disease.
A total of 483 patients died (243 in the sequential arm and
240 in the 5-FU/LV arm) and 581 patients recurred or died: 297
(52.8%) and 284 (52.8%), respectively.
Both DFS [HR for recurrence/death 1.00; 95% CI 0.85–1.17;
P = 0.974 (supplementary Figure S4, available at Annals of
Oncology online)], and OS [HR for death 0.98; 95% CI 0.82–
1.18; P = 0.865 (supplementary Figure S5, available at Annals of
Oncology online)] were overlapping between arms.
Adjustment for stratiﬁcation factors gave an HR for recur-
rence/death of 0.98 (95% CI 0.83–1.16; P = 0.805) and an HR of
death of 0.99 (95% CI 0.82–1.18; P = 0.877), as shown in supple-
mentary Table S6, available at Annals of Oncology online.
Five-year DFS rates were 44.6% (95% CI 38.9–50.3) among
patients in the sequential and 44.6% (95% CI 42.7–46.6) among
those in the 5-FU/LV group. Five-year OS rates were 51.0%
(95% CI 44.8–56.8) and 50.6% (95% CI 48.3–53.1), respectively.
The interaction analyses (supplementary Figures S7 and S8,
available at Annals of Oncology online) did not show any inter-
action for all considered variables both for OS and DFS.
discussion
Our randomized study failed to show any statistically signiﬁcant
beneﬁt in terms of both DFS and OS in patients with radically
resected GC receiving an adjuvant treatment with FOLFIRI fol-
lowed by docetaxel and cisplatin versus a 5-FU/LV regimen.
A recent Japanese study compared the following four different
adjuvant regimens: UFT alone, S-1 alone, or sequential therapy
with paclitaxel followed by either UFT or S-1. The trial was
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aimed at comparing UFT with S-1, and both single agents with a
sequential, taxane-based regimen. It failed to show a statistically
signiﬁcant difference in DFS of the sequential arms when com-
pared with single-agent ﬂuoropyrimidine arms (HR = 0.92; CI,
0.80–1.07, P = 0.273). Moreover, UFT-based chemotherapy was
clearly less effective than S-1-based one. Therefore, a sequential
polychemotherapy does not seem to improve GC patient
outcome in the adjuvant setting [9].
Since ﬂuoropyrimidine and platinum salts have synergistic ac-
tivity, their combination may hopefully be more effective than a
single-agent regimen; similarly, the CLASSIC study was
designed to compare the efﬁcacy of adjuvant capecitabine plus
oxaliplatin (XELOX regimen) versus surgery alone in stage II or
III GC patients [10]. At 5 years, DFS was 68% versus 53% (HR:
0.58; 95% CI 0.47–0.72; P < 0.0001). Five-year OS rates were
78% in the XELOX group and 69% in the surgery alone group
(HR: 0.66; 95% CI 0.51–0.85; P = 0.002). However, the greater
limit of this study is that the control arm consisted in surgery
alone that is considered no more appropriate, since the beneﬁts
of adjuvant chemotherapy were clearly demonstrated. Indeed,
the ongoing POTENT study is moving along this line. This is a
randomized trial that started enrollment in early 2013 and ran-
domizes patients to receive oxaliplatin and S-1 for six cycles or
S-1 for 1 year after surgery, having OS as the primary end point.
Another issue is that in our trial, a large proportion of
patients (75%) underwent at least a D2 lymphadenectomy and
the study conﬁrmed the high survival rates observed in previous
studies in the adjuvant setting [11–13]. Moreover, local recur-
rence developed in only 10% is likely the result of more exten-
sively lymph node dissection.
The frailty of GC patients after surgery combined with tox-
icity of adjuvant polychemotherapy could explain the poor com-
pliance to treatment and the lack of beneﬁt. In the present study,
sequential treatment was completed in 76.3% of patients but,
burdened with more frequent grade 3–4 hematologic and
gastrointestinal toxicities, only 16.7% completed treatment
without time and dose modiﬁcations. However, for this reason,
we believe that the treatment with FU/LV is enough and should
be a valid option in resected patients; further attempts to dose
intensiﬁcation will not increase the beneﬁt of adjuvant therapy
after radical gastric resection. Different is the role of polyche-
motherapy in preoperative phase and ongoing studies such as
CRITICS should give a response.
If the capability to improve patient outcome with current ad-
juvant therapies seems modest, at least in western countries, it is
possible to pursue different complementary research strategies.
First of all, a better patient selection according to molecular
tumor characteristics. ToGA study [14] showed the superiority
of the combination of trastuzumab with a ﬂuoropyrimidine
(5-FU or capecitabine) plus cisplatin every 3 weeks compared
with chemotherapy alone in terms of OS in patients with
advanced GC and HER2 protein overexpression. The assessment
of trastuzumab or novel anti-HER2 drugs in the perioperative
and adjuvant setting seems as a challenging perspective.
Different modalities of scheduling and combination therapies
could further improve the prognosis of GC patients.
Neoadjuvant chemotherapy has recently received attention in
an attempt to prolong survival. The available data indicate that
neoadjuvant chemotherapy is feasible and does not increase
adjuvant morbidity and mortality. In particular, several small
phase II trials on different neoadjuvant cisplatin-based chemo-
therapy regimens reported response rates between 40% and 60%
and R0 resection rates up to 80% [15, 16].
MAGIC trial [17] was the ﬁrst study that demonstrated a
beneﬁt of perioperative chemotherapy. Five-year survival was
36% in the perioperative chemotherapy versus 23% in the
surgery alone group, making the perioperative chemotherapy
the standard care in UK.
Although chemoradiotherapy in the adjuvant setting
improves survival based on the results of the INT-0116, the role
of this approach after a D2 dissection needs to be further investi-
gated [18]. This trial demonstrated that adjuvant radiotherapy
plus 5-FU chemotherapy signiﬁcantly improves recurrence-free
survival and OS of patients with locally advanced adenocarcin-
oma of the stomach or gastroesophageal junction. The surgical
procedure was considered inadequate since only 10% of patients
had D2 lymph nodes dissection and chemoradiotherapy treat-
ment reported a high rate of acute toxicity probably due to the
large ﬁeld of irradiation and to the radiotherapy technique used.
Moreover, in an update of INT-0116, a subset analysis showed
no differences in OS and DFS of patients who underwent a D2
nodal dissection compared with other patients [19]. Following
the promising results of the INT-0116 trial, the CALGB 80101
aimed at assessing whether replacing 5-FU/LV with Epirubicin,
Cisplatin, and 5-FU (ECF regimen) improve OS [20]. There was
no signiﬁcant beneﬁt from adding this polychemotherapy
regimen to standard 5-FU/LV chemoradiation in terms of OS.
Recently, a phase III trial conducted in Korea did not show a
survival beneﬁt for adjuvant chemoradiation therapy versus
chemotherapy, following a D2 surgery [21].
Up-to-date, the use of adjuvant chemotherapy is mainly
supported by positive results of two phase III trials in which
surgery alone was the control arm, since trials comparing poly-
chemotherapy or chemoradiotherapy versus an active control
failed to show any beneﬁt for patients [6, 10, 20, 21].
Despite this great number of trials, due to the strong limits
related to the differences in population characteristics and surgi-
cal techniques, any attempt to an indirect comparison exercise
appears inappropriate.
Therefore, FU/LV can be considered the standard treatment
in patients radically operated with D2 dissection.
Studies evaluating either HER2-oriented approaches or adju-
vant versus neoadjuvant chemotherapy with or without radio-
therapy are highly warranted.
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